Proactive therapeutic drug monitoring is more effective than conventional management in inducing fecal calprotectin remission in inflammatory bowel disease-Reference-Cited by-同舟云学术

Proactive therapeutic drug monitoring is more effective than conventional management in inducing fecal calprotectin remission in inflammatory bowel disease

Published:2021-03-12 Issue:12 Volume:33 Page:1539-1546
ISSN:0954-691X
Container-title:European Journal of Gastroenterology & Hepatology
language:en
Short-container-title:

Author:

Fernandes Samuel Raimundo,Serrazina Juliana,Rodrigues Inês Coelho,Bernardo Sónia,Rita Gonçalves Ana,Valente Ana,Baldaia Cilénia,Santos Paula Moura,Correia Luís Araújo,Tato Marinho Rui

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Gastroenterology,Hepatology

Reference28 articles.

1. Inflammatory bowel disease: clinical aspects and established and evolving therapies.;Baumgart;Lancet,2007

2. Systematic review with meta-analysis: mucosal healing is associated with improved long-term outcomes in Crohn’s disease.;Shah;Aliment Pharmacol Ther,2016

3. Mucosal healing restores normal health and quality of life in patients with inflammatory bowel disease.;Casellas;Eur J Gastroenterol Hepatol,2012

4. Fecal calprotectin as predictor of relapse in patients with inflammatory bowel disease under maintenance infliximab therapy.;Ferreiro-Iglesias;J Clin Gastroenterol,2016

5. Infliximab, azathioprine, or combination therapy for Crohn’s disease.;Colombel;N Engl J Med,2010

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Infliximab serum concentrations in luminal Crohn's disease and its relationship with disease activity: A multicentric cross-sectional study;Gastroenterología y Hepatología (English Edition);2024-08

2. Is infliximab therapy currently relevant in patients with inflammatory bowel diseases? (review);Koloproktologia;2024-06-21

3. HLA-DQA1*05 correlates with increased risk of anti-drug antibody development and reduced response to infliximab in Chinese patients with Crohn’s disease;Gastroenterology Report;2023-12-22

4. Infliximab serum concentrations in luminal Crohn's disease and its relationship with disease activity: A multicentric cross-sectional study;Gastroenterología y Hepatología;2023-12

5. Proactive Infliximab Monitoring Improves the Rates of Transmural Remission in Crohn’s Disease: A Propensity Score–Matched Analysis;Inflammatory Bowel Diseases;2023-11-20